US Stock MarketDetailed Quotes

GSK GlaxoSmithKline

Watchlist

33.470
-0.480-1.41%

Close Jan 3 16:00 ET

33.750
+0.280+0.84%

Pre 07:17 ET

68.29BMarket Cap22.19P/E (TTM)

GlaxoSmithKline Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

GlaxoSmithKline Q3 2024 Earnings Date

Currency：USDOct 30, 2024

	Estimate (YoY)	Actual (YoY)	Vs Estimate (% Chg)
Revenue	10.71B	10.72B	+6.88M
Beat Est.	+7.72%	+7.79%	+0.06%
EPS	0.16	-0.04	-0.19
Miss Est.	-83.36%	-104.31%	-124.08%

Analyst Rating

Hold

Dec 31, 2024

GlaxoSmithKline Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: GBP

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q1	-- / 7.510B	--
--	2024/Q4	-- / 7.681B	--
Oct 30, 2024	2024/Q3	8.012B / 8.007B	--
Jul 31, 2024	2024/Q2	7.884B / 7.493B	--
May 1, 2024	2024/Q1	7.363B / 7.060B	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q1-- / 7.510B--

--2024/Q4-- / 7.681B--

Oct 30, 20242024/Q38.012B / 8.007B--

Jul 31, 20242024/Q27.884B / 7.493B--

May 1, 20242024/Q17.363B / 7.060B--

Unlock Free Earnings Estimates

Open Account

GlaxoSmithKline Earnings Reports

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

Oct 30, 2024 11:27 ET

6-K: Gsk Delivers Continued Strong Performance and Upgrades 2024 Guidance

Jul 31, 2024 12:31 ET

6-K: Gsk Makes a Strong Start to 2024 with Improving Outlook for the Year

May 1, 2024 12:34 ET

GlaxoSmithKline | 6-K: Glaxosmithkline 2023 Annual Report on Form 20-F

Mar 5, 2024 13:13 ET

Trending US Stocks

Symbol Mini Chart % Chg

DexCom

DXCM

+3.27%

Collegium Pharmaceutical

Unlock the Full List

Analysis

Analyst Rating

Updated: Dec 31, 2024

Hold

Buy
20.00%
Hold
60.00%
Sell
20.00%

Price Target

No Data